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A n e w pa pain inhibitor was purified from psoriatic 
epide rmal scales using gel chromatography and anion 
exchange chromatography . The purified protein inhib-
ited papain and ficin but not cathepsin B, cathepsin H , 
try psin, or chy motrypsin. lsoelectric focusing revealed 
3 major inhibitor variants with pi's of 7.3, 6 .9, and 6.5. 
A Mr of 38,000 was obtained by a gel chromatographic 
method for the crude inhibitor. After sodium dodecyl 
s ulfate-polyacrylamide gel electrophoresis the Mr values 
o f the isoelectric variants were: 43,000 for the variant 
pi 7.3, 4 3,000 and 35,000 for the variant pi 6.9, and 
3 4 000-35 ,000 for the varia nt pi 6.5. An antiserum of 
th~ inhibitor was used to locate the inhibitor in the 
psoriatic and normal epidermis. In psoriatic epidermis, 
t he inhibitor was found in the peripheral cytoplasm of 
s pinous cells and in the scale. In normal epidermis, the 
staining was seen only in orifices of hair follicles. An 
inhibitor with similar size and antigenic properties to 
t hat isolated from the psoriatic scales was demonstrated 
in e xtracts made from the whole-thickness epidermis 
but not in extracts from the healthy epidermal scales, 
the d e rmis, the liver, the spleen, or the blood serum. 
Huma n t issues are known to conta in 3 ant igenically and 
b ioch emica lly diffe rent cysteine proteinase inhibitors. Acid cys-
te ine prote inase inhibitor (ACPI ) [1] has a M~ of abou~ 12,600 
a nd a n isoelectric poin t of 4.7- 5.0. It was fi rst Iso lated from t he 
hum a n epidermis (epidermal SH -protease inhibi tor) [2]. Neu-
t r a l cyste ine proteinase inhibitor (NCPI) h~s a _M, of a?out 
12 000 a nd isoe lectric point of 6.0- 6.5. It was hrst Isolated from 
th~ s pleen [1]. Alpha cyste ine proteinase inhibitor (a -CPI) is 
found in human plasma [3] and is composed of 2- 3 van ants 
wit h different molecular sizes (90 ,000- 170,000) and charges 
[4) . . . h . 
T h ere are three published studies dealing w1t cysteme pro-
t e inase inhibitors in psoriatic epidermis. Oh ta ni et a l [5] found 
t hat t he concent ration of cysteine proteinase inhibitor was 
incr eased in pso riatic, as compared to normal, epidermis. The 
partia lly puri fied inhibi tor had the same molecul_a r size and 
was a n t igenically iden tica l to t hat in t he normal ep1dermts, bu t 
t her e we re differences in t he stabili ty and inhibi t ion propert ies 
of t h e inh ibitors in healthy and diseased epidermis. Hopsu-
Havu et a l [6) used quant itative radioimmunochemical methods 
[7 ,8) to study t he amounts of ACPI and NCPI. in psoriatic 
ep ide rmis. They showed that ACPI concentration was Ill -
creased in pso riati c epidermis, and NCPf- which is not present 
in h ealt hy epidermis- was also present. Later, t hey also dem-
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onstrated a previously unknown papain -inhibit ing peak in t he 
pso riatic ep idermis [9]. 
In t he present publicat ion we describe t he purification as 
we ll as some characteristics of t hi s inhibi tor and describe its 
location in t he psoriatic and normal epidermis. A preliminary 
report of t his work has been previously published [10]. 
MATERIALS AND METHODS 
Materials 
Papain (for biochemical purposes) was obta ined from E. Merck, 
A.G., Darmstadt . Mercur ipapain , {icin (crude), t rypsin (bovine, type 
Ill ), chymot rypsin (bovine, type II ), azocase in, bovine se rum album in 
(c rys ta llinen) , ova lbum in (grade V ), chymot ryps inogen A (bovine, 1ype 
ll ), cytoc hrome C, dit hiothreitol, a nd Coomassie Brilliant Blue R. were 
obta ined from S igma Chemica l Co mpa n.v, St. Louis, Missouri. 
N, ,N ' ,N ' -tet ra methyl ethylenediam ide, N ,N ' -methylenebisacrylam-
ide, a nd ac ryla mide were obta ined from Eas tman-Kodak , Rochester, 
New York . Benzoyl-DL-a rginine-2- naphthylamide hydrochloride a nd 
2- mercaptoet ha nol were obt a ined from Fluka AG , Buchs, Swi tzer la nd. 
Sep hadex G-75 a nd DEAE-Sephacel were obt a ined from P ha rmaci11 
Pine Chemicals, Uppsa la, Swede n, a nd Amp holine carrier ampholytes 
from LI< B P roducts, B romma, Sweden. Polyvalent a nt iserum of huma n 
serum proteins (rabbit o rigin ), swine a n t. i s~rum of rabbi t immunoglob-
ulins, a nd rabbit peroxidase-a nt ipe roxidase complex were obtained 
from Dakopatts, Copenhagen, Den ma rk . ACP l, NCP I. Ct·-CP l, and their 
a ntisera were p repa red as descri bed ea rli er [1 - 3 j. Huma n liver cal h-
epsin H a nd B were prepa red as described by Schwa rtz a nd Ba rrett 
[11] . T he spe ific benzoyl-DL-argin ine-2-napht hylam ine hydrolyz ing 
act ivity of the purifi ed cathepsin B was 3.8 J.l mol X min- 1 x mg- 1 and 
that of ca t hepsin H was 0.9 J.l mol x min- 1 x mg- 1• 
Assay Methods 
The a moun ts of enzymes in \ he assay mi xt ures (400 1d ) were: papa in 
5 J.l g, fi c in 5 pg, mercuripapa in 1 pg, cat hepsin B 2 pg, cat hepsin H 2 
pg, t rypsin 5 pg, a nd chymotrypsin 5 J.lg. T he subs\ ra tes used we re: 1.25 
mM benzoyl-DL-a rginine-2- nap hthylam ide hydroc hloride (4% metha-
nol) for papain. mercu ripapain , fi c in , ca t hepsin B, and ca t hepsin H, 
a nd 1.5% (w/ v) azocasein fo r trypsin a nd chymotryps in . Buffers and 
act iva t.o rs were as described earl ier [2,3 ]. T he unit of inhibition was 
defi ned as the amounL of enzyme (mg) inh ib ited by 1 ml of in hibi to r 
so lution (U/ ml) or by I mg of inhibitor prolein (U/ mg) . 
T he method of Lowry et a l [12] was used t.o assay protein co ncen-
t ra t ions with bovine serum a lbum in as a sta nda rd. T he protein concen-
t ra t ions oft he chromatography fract ions were estima ted by measurin g 
their absorbance a t 280 nm. . 
Tissu.e Sample:; 
. No rma l st ratum co rneum was collected by scrapi ng t.he trunk skin 
of cadavers durin g autopsy. The whole-thickness huma n ep iderm is was 
sepa rated fro m \.he dermis by scrap ing the stretched skin wit h a sca lpel. 
Scales of psoriat ic skin we re obta ined by gently scraping the skin of 
un t reated patients. T he sca les of 10 pat ients were combi ned. 
Purification Methods 
. Extraction: Extraction was performed by homogenizing 1 part of 
t1ssue tn 10 pa rts of 10 mM Tris-HCl buffer, pH 7.6, using a conica l 
f(lass homogenizer. The homogenates were a llowed to stand at o·c fo r 
20 min a nd t hen cent ri fuged a t + 5•C, a t 12,000 g. The supernat.ants 
were used for fur t her puri fication o f t he inhibitors. 
Gel Ch romatography: A colu mn wit h di mensions of 2.6 em x 34 em 
was packed with Sephadex G-75 and equilib ra ted wi th 10 mM T ris-
HCl, pH 7.6, in a cold room (+5. C). Ext racts (6.0 ml ) were applied al 
a fl ow rate of 15 ml / h a nd fracl ions of 5.0 ml were co llected. T o 
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estim ate molecular s izes of the eluted proteins t he column was ca li -
bra ted using Blue Dextran, bov ine se rum albumin (M, = 68,000) , 
ova lbum in ( M, = 45,000), chymotryps inogen A (M, = 25,000), and 
cytoch rome C (M, = 12,300). 
DEA E-Sephacel Chromatography: A 1.5 x 2 .. 5 em co lumn was packed 
wit h DEAE-Sephacel and equilibrated with 10 mM Tris- HCl buffer, 
pH 7.6 (a t. +5"C). T he pooled inhibito r from the Sephadex G-75 
chromatography was applied to the column at a fl ow rate of 15 ml/ h 
and 5- ml frac tions were collected. T he unabso rbed proteins were eluted 
with the equilibratin g butTer (50 mil and the absorbed proteins wit h a 
NaCI gradiem in the buffer (0- J.50 mM Na CI, tota l volume 400 ml) . 
T igl1Lly abso rbed proteins were removed with 200 mM NaCl in t he 
buffer and t.he column was reequilib rated. 
Prepara tive lsoelectn:c Focusing: A 110-ml Ampholine (LKB , 
Bromma, Sweden) apparatus and a mixture of Ampholine carrier 
ampholyt.es (2.5 ml of pH 5- 8 and 0.5 ml pH 3.5- 10) were used, with 
the anode on top. 
Polyacry lamide Gel Electrophoresis 
Gel elenrophoresis in sodium dodecyl sulfate-conta ining 12.5 % poly-
ac rylamide ge l was performed as described by Laemm li [ 13]. 
l mm.u.rwlogic and Immunohistochemical Methods 
The inhibito r va riants with isoelectric poin ts of 7. 3, 6.9, a nd 6.5 were 
used to immunize rabbits usin g the immunization procedure desc ribed 
earlier [14 ]. Double radial immunodiffusion and immunoelectrop ho-
resis in Tris-glyci ne-diethyl ba rbiturate-buffered agarose gels (I = 
0.025) were used 1.0 study ant igen-a nt ibody reactions. The anti-inhibi -
tor serum used in immunohistochemical localizations was absorbed 
with sca les of the norma l epidermis: 10 mg of scales was added to 1 ml 
of the antise rum a nd dispersed by stirri ng wi t h a glass rod. The 
. uspension was ge nt ly mixed overnight at +5"C and then centrifuged 
at 12,000 g ror 30 min. The supernatants were used in immunohisto-
chemist ry. Sa mples of' normal and psoriatic skin were eithe r (a) cut 
in to frozen sect ions or (b) li xed in 4% formaldehyde in 0.25 M sucrose, 
.LO mM Tris- HCI, pH 7.4, for 4 h at room temperature, washed overn ight. 
in 0.25 M sucrose, 10 mM T ris- HCl, pH 7.4 , and cut into frozen sect ions 
on a lhum inized s lides. The unlabeled perox idase-antiperoxidase com-
plex method of Sternberge r [1 5]. modified as in [1 6], was used to 
localize t he inhibitor. Triton X-100, in concent rations described by 
Hartman [1 7], was included in the a ntibody and washing solutions to 
improve the permeability of t.he prelixed froze n sections. The specdicity 
of the immunohistoc hemica l stai ning was controlled by replacin g the 
anti -inhibitor serum with preimmun e serum . 
RESULTS 
Purificat ion of the I nhibitor 
Gel filtration o n Sephadex G -75 separated the papain-inh ib -
it ing protein s o f the psoriatic scale extract in to two act ivi ty 
peaks, I and II (Fig 1a). T he e lution volume of peak l corre-
sponded to a M, o f abou t 38,000 and that of peak II to about 
12,000. Extracts fro m t he whole-thickness norm al ep idermis 
a nd surface-scraped epidermal scales were a lso fraction ated in 
the same Sephadex G -75 column (Fig lb,c). O nly peak II was 
fo und in the no rma l epidermal scale extract, whi le the extract 
fro m t he whole-thickn ess epide rmis con tained bot h pea k I and 
peak ll. Immunodiffus io ns aga inst antisera of ACPI a nd N CPI 
s howed t hat peak II o f t he psoriatic scale extract contained 
both ACPI a nd NCPl, while peak ll of t he normal epiderm a l 
s urface scales or whole -t hickn ess epide rmis contained only 
ACPl (cf [6] ). T he proteins in peak l did not form precipitates 
with t he ant iserums o f ACPJ or NCPl. No reactio n wit h anti-
O'·CP I was found in a ny papain inhibiting peak. The resul ts 
s uggest t hat t he papa in inhibitor in peak l is a new, previously 
undesc ribed inhib itor. Peak 1 of psoriatic scale extract's Seph -
a dex G-75 chromatograp hy was pooled a nd further purified by 
a nion exc ha n ge c hromatography on DEAE-Sephacel (Fig 2). 
One papain -inhibiting pea k was eluted with t he equili brating 
buffer (peak A) and t he NaC I grad ient e luted furt he r 2-3 
partially ove rlapping papain -inhibi t ing peaks, t he highest ac-
t ivity be in g eluted with a NaC l conce ntration of 23 mM (peak 
B) . Peaks A a nd B d id n ot inhib it cathepsins B or H , whi le a 
weak inhibi tion was found in fraction 50. It most like ly repre-
sen ts traces of ACPI. 
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F IG 2. Fractionation of t.he papain inhibitor in the pooled peak I 
(F rom Fig I a) on DEAE -Sephacel. Two major papain inhibi tor peaks, 
A and B, were eluted. Peak A was slightly ret.arded when elu ted with 
the equilibratin g buffer (10 mM Tris- HCl, pH 7.6) a nd peak B was 
eluted with the NaCI gradient at a NaCI concent ration of 23 mM. Pea k 
B was partia lly divided into 2 activity peaks. 
The papa in -inhibi t ing peaks A (fractio ns 10- 18) a nd B (frac-
t io ns 35-46) were pooled separately. The results of their puri-
fication a re summarized in Table I. 
Properties of the Purified inhibitors 
!soeiectric Variants: The papa in-inhibitor pea ks A and B 
fro m the DEAE-Sephacel chromatogra phy were fractio n ated 
separately by isoe lectric focusi ng in a sucrose gradien t (Fig 3) . 
From preparation A, 1 papain-inhibiting activity peak focused 
at pH 7.3 , while 3 peaks focused from preparation Bat pH 6.9, 
6.5 , a nd 6.2. No peak inhibited cathep s in B or H. 
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TABLE I. Purifica tion of the new papain inhibitor from psoriatic 
epidermal scales 
Extract 
Sep h adex G-75 
Pool J 
Pool II 
DEAE-Sephace l 
Pool A 
Pool B 
I 
0.08 
~ 0.04 E 
-:::::::> 
c: 
0 
Vo l (ml ) Protein (mg) 
6.0 39.0 
20.0 8 .8 
25.0 5.3 
25.0 0.83 
30.0 1.44 
Papain inhibi tion 
(U/mg) (U) 
088 34.3 
0.95 8.4 
4.33 22 .8 
2.42 2.0 
2.71 3.9 
A 
9 
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5 
3 
-+- :r: 
..Cl D. 
...c 
c: 
c: 0 .08 ro 9 
0.. 
ro 
0.... 7 
0 .04 5 
3 
10 30 50 
Fraction number 
F t G 3. [soelec tric focusing oft he purified papain inhibi to r prepara-
tio n s A a nd B from t he DEAE-Sephacel chromatograph. From prepa-
rat ion A , 1 papa in -inhibi ti ng peaks was focused at pH 7.3. From 
p r e p a ration B, 2 major peaks we re focused at pH 6.9 and 6.5. In 
a dditio n to those, 2- 3 minor, more acidic peaks were see n. 
D egree of Purity and Molecular Weight: The results of a 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis of 
the inhibitor preparations A and B, and of their isoelectric 
variants are presented in Fig 4. The inhibitor seems to be 
composed of 2 distinct polypeptides wit h M , values of 43,000 
and 35 000 so that the varia nt pi 7.3 contains the larger polype;tid~ while the variant pi 6.9 contains both polypeptides. 
T h e M , values of t he variant pi 6.5 were 34,000-35,000, the 
s maller molecule possibly being a degradation product of t he 
larger . Identical molecular weight patterns were obtained with 
or without reduction of the samples with 2-mercaptoethanol, 
suggesting that t he polypeptides were not linked by cystine 
bridges to each other. 
Storage and Stability: The purified papain inhibitors (from 
t he DEAE-Sephacel chromatography) were 100% stable in a 
freezer ( -20"C) for more than 9 months, and in a refrigerator (+5 . C) for more than 2 months, when bacterial growth was 
prevented by adding 0.1% NaN,, to them. The inhibitors were 
stable at 60"C for 10 min , but were inactivated 20- 25% at 70"C 
a nd approximately 80% at 80"C. 
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F IG 4. Sodi um dodecyl sulfate-polyac rylamide ge l elect rophoresis. S = mixture of s ta nda rd proteins (bovine se rum a lbumin , M, = 6R,OOO: 
ova lbumin , 1\1, = 45,000; chymotrypsinogen A. 1\1, = 25,000; a nd C~' t.o ­
chrome C, M , = 12,300). Lanes I and 2 : 25 pg of p repa ration A from 
t he DEAE-Sephace l chromatography. Lanes 3 and .J: 25 pg of prepa-
ration B from the DEAE-Sep hace l chroma tography. Lanes 5 and 6: isoelect ri c variant p i 6.9. Lanes 7 and 8 : isoelectri c va riant p i 6.5 . 
Lanes 9 and / 0 : isoelec t.ric va ria nt pi 7.3. The samples with even 
numbers were heated (5 min a t 90. C) in the presence of l % sodium 
dodecyl sul fate a nd 10 mM 2- mercaptoetha nol; sa mples wit.h uneven 
num bers were incubated without 2- mercaptoethano l. Because of the 
presence of Ampholines in the electrofocused inhibi tor preparations, 
the exac t amounts of proteins in the samples of isoelect ri c va riants (la nes 4- 1 0) were no t known. 
lnh ibit.ion Spectrum: The purified inhibitors from DEAE-Sephace l chromatography inhibited t he plant cysteine pro-
te inases papa in and fi cin but did not inhibit the human cysteine 
proteinases cathepsins B or H , or t he bovine serine proteinases 
t rypsin or chymotrypsin under conditions described in Mate-
rials and Methods. Preincubation of the enzymes with the inhibitor for 1- 120 min did not affect t he inhibition of any of 
t he enzymes. The activi ty of mercuripapain decreased linearly 
with t he inhibitor concent ration down to 3-5% residual activity (Fig 5). Assuming molecular weights of 25,000 and 43,000 for 
papain and t he inhibitor, respectively, a molar ratio of 1.2 was 
obta ined for the prepa ration B-mercuripapain complex. T he 
inhibi t ion was apparently noncompetetive and an K; of 2 X 10-s M was obtained by using t he method of Myers [18] . 
Immunologic Properties: Immunization of rabbits wi t h the isoelectric variants pi 7.3, 6.9 , and 6.5 induced production of 
ant iserums. In double radial immunodiffusion these ant ise rums 
precipi tated the 3 isoelectric variants as well as a protein in the 
extracts made from psoriatic scales and normal whole-thickness 
epidermis. An immunoreactive inhibitor was not found in t he 
normal epidermal scales, the serum, the dermis, t he live r, or 
the spleen. The antiserums did not precipitate ACPI , NCPI, or 
a-CPI , and , vice versa, anti -ACPJ, a nti-NCPI, or anti-{1'-CPI 
did not precipitate the inhibitor preparations A or B. 
Immunoelectrophoretic ana lysis (Fig 6) revealed t hat t he 
antise rums of t he 3 inhibitor variants reacted with 2 immuno-
logica lly related proteins, which may refl ect t he isoe lectric 
hete rogeneity of t he inhibitor. The antiserums also recogni zed 
a cationic protein . This cationic protein was seen in the extracts 
made of pso ri atic as well as normal epidermal scales and it probably represents some conta mination in t he immunization 
preparations. The unwanted antibody in t he anti-inhibitor 
serums could be removed by absorbing t he ant iserums with 
normal epidermal scales as described in Materials and Methods. 
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F IG 5. T he effect of t he a moun t. o f the inhibi to r prepa ration B on 
the activity of mercuri papa in (1.0 J.Lg in t he assay mi xture of 400 J.Ll ). 
Assu mi ng t he molecu la r we ight of t he inhibito r to be 43,000 a nd t hat 
of papain to be 24,500, a mola r rat io of 1.2 was calculated fo r t he 
inhibito r-enzyme complex at t he equiva lent poin t. 
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FIG 6. 1 mmunoelec1 rop horesis, I = 10 J.L l of an ex tract from psoriatic 
sca les (6 .5 mgjm l of protein). 2 = 20 J.Ll of a n extract from normal 
epidermal sca les (2. 1 mg/ml of prote in ). A-6.5, A-6.9, A -7.3 : 100 J.Ll of 
a ntisera against varia nts p i 6.5, 6 .9, a nd 7.3. A -Ser = 100 J.Ll of 
polyva lent a ntiserum aga inst se ru m p rote ins. Note t he strong double 
a rchs prec ip itated from t he pso ri atic sca le extract a nd the abse nce of 
t he precipi tates from t he norma l ep idermal sca le extract. The cathoda l 
prec ipitate archs fo rmed wit h a n a nt ige n in t he pso riatic a nd norma l 
epide rma l sca le ex tracts revea l t he unspecificity of the ant ise rums. 
Loca.lizaLion: T he ant iserum of t he variant pi 6.9, which was 
absorbed wit h the normal epidermal scales, was used to locate 
the inhibito r in pso riatic and normal epidermis. In Fig 7 t he 
location of t he inhibito r in a frozen section of formalin-fixed 
psoriatic sk in is shown. T he inhibitor is seen in t he cytoplasm 
of t he sp inous cells as well as in t he stratum corneum . The 
staining is weaker in the basal laye r t han in the suprabasal cell 
layers. ln F ig 8 a detail of t he psoriatic epidermis is seen in 
higher magnifi cation. The reaction is most intense in t he 
pe riphery of the cytoplas m. The intercellular spaces are not 
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stained. In a cont rol experimen t where preimmune serum was 
used instead of t he ant i-inhibito r se rum, only ve ry pa le back -
ground staining was seen. In normal epidermis (Fig 9) t he 
sta ining was weak a nd was seen only in orifices and inne r root 
sheaths of hairs. The staining of an unfixed frozen section of 
normal epidermis resembled that depicted in Fig 9, but a n 
addit ional weak sta ining of interce llular spaces of t he epidermis 
was seen (data not shown). 
DISCUSSION 
T he papa in-inhibi t ing protein iso lated in the presen t work 
seems to be a new, previously undescribed prote inase inhibitor , 
which diffe rs both biochemically and immunologically from 
ACPI, NCPI, and a-CPI. The s imple purification procedure 
described herein produced a highly purified inhibitor. The 
relatively low purification coeffi cient (2.7-3.0) can be expla ined 
by the presence of ACPI and NCPI in t he extract and by losses 
of t he inhibitor during purification. Even t he most purified 
isoe lectric variants of t he inhibito r, however, seemed to con ta in 
some antigen ic impurity (cf Fig 6). The present inhibitor was 
not noticed by Ohtani et a! [5] in t heir investi gation of cys teine 
prote inase inhibito rs of t he pso riatic epidermis. A probable 
reason for t his was the heat t reatment t hey used, which appears 
to destroy t his inhibitor . 
fi' IG 7. Loca lization of t he in hibi to r in pso n attc sk in using the 
unlabe led perox idase-a nt ipe rox idase method . Frozen section of for-
malde hyde-fi xed t issue a nd a nt ise rum (dilu t ion 1:800) to variant pl 
6.9, absorbed wit h norma l epide rmal sca les , were used . Strong cyto-
p lasmic sw ining is seen in a ll supmbasa l ce ll laye rs of the epide rm is 
a nd in t he sca le. The arruw indica tes t he de rmal-epide rma l junction . 
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FIG 8. A detail o f' Fig 7. The sta ining is located in the periphery or 
the cytoplasm a nd extends to the desmosomes, but t he mtercellular 
space is negative. 
FIG 9. Locali1.ation or the inhibitor in normal ~k in. The conditions 
were as in Fig 7. Pos itive staining was seen only in the ha ir follicle 
orifice (a) and in the inner root sheath of ha irs (b) . 
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The inhibitor from t he psoriatic epidermis inhibi ted t he plant 
cysteine proteinases papain and ficin , but not t he mammalian 
lysosomal cysteine proteinases cathepsin B and cathepsin H , 
or t he se rine proteinases tryps in and chymotrypsin. The Jack 
of inhibition of mammalian enzymes makes it difficult for us 
to interpret the role of the isolated inhibitor as a regulator of 
proteinase activities in t he epidermis. Cysteine proteinase in -
hibitors a re known to differ in their spec ificit ies [19-22) and 
perhaps t he prote inase inhibited in vivo is an epidermal cys-
teine proteinase not tested by us. 
The inhibitor can eas ily be located in the psoriatic epidermis 
by using frozen sections of formaldehyde-fixed tissue and an 
antiserum absorbed with normal epidermal scales. The location 
was simila r to that described by us ea rlier [10] using paraffin 
sections and t he unabsorbed antiserum of variant pl 6.5, but. 
the present method allowed the use of 8 t imes more dilute 
antiserum. In t he normal epidermis, however, t he location was 
different from that obtained with the previous method, which 
stained the granu lar layer cells and the stratum corneum. The 
differences may be explained as caused by another antiserum, 
or by differences in the absorption and dilution of the antisera. 
Of several t issues studied by us, only psoriatic epidermis and 
to some extent normal epidermis (possib ly also esophagea l 
epit helium) contai ned t he present inhibi tor. Although quanti-
tative data are not available at present, t he concentration of 
the inhibitor in psoriatic epidermis is severalfold higher t han 
t hat in normal epidermis (cf Figs 1, 6, 7, 9). In addition, the 
inhibi tor in psoriatic epidermis is transferred in soluble form 
into t he sca les, while in the normal epidermis it cannot be 
extracted from t he stratum corneum. These facts suggest that 
t he present inhibitor may somehow be involved in the patho-
ge nesis of psoriasis. The behavior of t he inhibitor in other 
disorders of the epidermis is under investigation . 
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